Recently, adjuvant osimertinib with or without chemotherapy greatly improved DFS, with a hazard ratio of 0.17 and OS with a hazard ratio of 0.49, in patients with stage II/IIIA NSCLC with EGFR mutations [20,21,22,23]. Here, EGFR is linked to non-small cell lung carcinoma.